Shamburg News · 8-K filed Nov 17, 2026, 9:44 AM EST
Viatris completes $36.50-per-share cash acquisition of Pacira BioSciences
VTRS · Viatris Inc
- Acquisition
- Financing
- Reg FD disclosure
- Delisting
- Materiality: high
Viatris Inc. completed its acquisition of Pacira BioSciences, Inc. on November 17, 2026, after its tender offer at $36.50 per share in cash expired on November 16, 2026. A total of 32,929,780 shares, approximately 66.46% of those outstanding, were validly tendered and accepted for payment. Purchaser then merged with and into Pacira under Section 251(h) of the DGCL, leaving Pacira as a wholly owned subsidiary of Viatris. The aggregate payment is approximately $1.69 billion, funded with cash on hand and short-term borrowings, and Viatris expects Pacira to contribute total revenues of $90 million to $100 million for November 17 through December 31, 2026.
Source: SEC EDGAR, Form 8-K, Items 2.01, 7.01, accession 0001140361-26-044356.
Written from the filing by Shamburg Markets. Figures are as reported by the company.